Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of on-demand GSK557296 for premature ejaculation
NL-OMON35560Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epelsiban in premature ejaculation (PE) (3 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Dec 2009; status: active, not recruiting.
02
Drugs
epelsiban
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NL-OMON35560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35560.